COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

Cong Zeng; John P Evans; Karthik Chakravarthy; Panke Qu; Sarah Reisinger; No-Joon Song; Mark P Rubinstein; Peter G Shields; Zihai Li; Shan-Lu Liu

doi:10.1016/j.ccell.2021.12.014

COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

Cancer Cell. 2022 Feb 14;40(2):117-119. doi: 10.1016/j.ccell.2021.12.014. Epub 2021 Dec 30.

Authors

Affiliations

¹ Center for Retrovirus Research, Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, USA.
² Center for Retrovirus Research, Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, USA; Molecular, Cellular and Developmental Biology Program, Ohio State University, Columbus, OH 43210, USA.
³ Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
⁴ Comprehensive Cancer Center, James Cancer Hospital, Ohio State University, Columbus, OH 43210, USA.
⁵ Comprehensive Cancer Center, James Cancer Hospital, Ohio State University, Columbus, OH 43210, USA. Electronic address: Peter.Shields@osumc.edu.
⁶ Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Electronic address: Zihai.Li@osumc.edu.
⁷ Center for Retrovirus Research, Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, USA; Viruses and Emerging Pathogens Program, Infectious Diseases Institute, Ohio State University, Columbus, OH 43210, USA; Department of Microbial Infection and Immunity, Ohio State University, Columbus, OH 43210, USA. Electronic address: Liu.6244@osu.edu.

No abstract available

Publication types

Comparative Study
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

2019-nCoV Vaccine mRNA-1273 / immunology*
Adult
Aged
Antibodies, Neutralizing / immunology*
Antibodies, Viral / blood
Antibodies, Viral / immunology*
BNT162 Vaccine / blood
BNT162 Vaccine / immunology*
COVID-19 / epidemiology
COVID-19 / prevention & control*
COVID-19 Vaccines
Humans
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use
Immunization, Secondary*
Immunogenicity, Vaccine
Middle Aged
Neoplasms / immunology*
Neoplasms / therapy
SARS-CoV-2 / genetics
SARS-CoV-2 / immunology*
Spike Glycoprotein, Coronavirus / genetics
Spike Glycoprotein, Coronavirus / immunology
Vaccine Efficacy

Substances

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
Immune Checkpoint Inhibitors
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine

Supplementary concepts

COVID-19 breakthrough infections
SARS-CoV-2 variants

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding